Serum Adiponectin Levels in Patients with Acute Coronary Syndromes: Serial Changes and Relation to Infarct Size

Overview

Journal Diab Vasc Dis Res

Publisher Sage Publications

Specialty Cardiology & Vascular Diseases

Date 2015 Jul 22

PMID 26193887

Citations 1

Authors

Hadeel Alkofide

Gordon S Huggins

Robin Ruthazer

Joni R Beshansky

Harry P Selker

Affiliations

Soon will be listed here.

Abstract

Background: The role of adiponectin in patients with acute coronary syndromes is incompletely defined. This study investigated adiponectin levels in patients with acute coronary syndromes and the association between adiponectin and 30-day infarct size and 1-year clinical outcomes.

Methods: Retrospective analysis of 120 participants with acute coronary syndromes enrolled in the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care Trial. Blood levels were tested three times within 24 h of onset of ischaemic symptoms. Infarct size was measured at 30 days. The 1-year clinical outcome was the composite of all-cause mortality or hospitalization for heart failure.

Results: Using linear mixed models, log adiponectin levels decreased by -0.005 µg/mL per hour (p = 0.035). After stratifying the analysis by gender, there was no decrease in log adiponectin in men; however, levels decreased by -0.01 µg/mL per hour in women (p = 0.02). Results of multivariable regression models showed no association between log adiponectin and infarct size (β = -1.1, p = 0.64). Log adiponectin levels did not predict 1-year outcomes using Cox-proportional hazard models.

Conclusion: There was a small decrease in plasma adiponectin shortly after symptoms of ischaemia, more noticeable in women. No relationship was found between adiponectin and infarct size or clinical outcomes. This adds to evidence showing no clear association between adiponectin and adverse outcomes in patients with acute coronary syndromes.

Citing Articles

Significant Association of Serum Adiponectin and Creatine Kinase-MB Levels in ST-Segment Elevation Myocardial Infarction.

Natsukawa T, Maeda N, Fukuda S, Yamaoka M, Fujishima Y, Nagao H J Atheroscler Thromb. 2017; 24(8):793-803.

PMID: 28100880 PMC: 5556187. DOI: 10.5551/jat.38232.

References

Onat A, Hergenc G, Dursunoglu D, Kucukdurmaz Z, Bulur S, Can G . Relatively high levels of serum adiponectin in obese women, a potential indicator of anti-inflammatory dysfunction: relation to sex hormone-binding globulin. Int J Biol Sci. 2008; 4(4):208-14. PMC: 2491727. DOI: 10.7150/ijbs.4.208. View

Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, Takahashi M . An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res. 2000; 32(2):47-50. DOI: 10.1055/s-2007-978586. View

Spranger J, Kroke A, Mohlig M, Bergmann M, Ristow M, Boeing H . Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003; 361(9353):226-8. DOI: 10.1016/S0140-6736(03)12255-6. View

Rathmann W, Haastert B, Herder C, Hauner H, Koenig W, Meisinger C . Differential association of adiponectin with cardiovascular risk markers in men and women? The KORA survey 2000. Int J Obes (Lond). 2006; 31(5):770-6. DOI: 10.1038/sj.ijo.0803471. View

Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S, Hirose M . Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart. 2004; 90(5):528-33. PMC: 1768199. DOI: 10.1136/hrt.2003.011114. View

Kondo K, Shibata R, Unno K, Shimano M, Ishii M, Kito T . Impact of a single intracoronary administration of adiponectin on myocardial ischemia/reperfusion injury in a pig model. Circ Cardiovasc Interv. 2010; 3(2):166-73. PMC: 3668696. DOI: 10.1161/CIRCINTERVENTIONS.109.872044. View

Lindsay R, Resnick H, Zhu J, Tun M, Howard B, Zhang Y . Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol. 2005; 25(3):e15-6. DOI: 10.1161/01.ATV.0000153090.21990.8c. View

Selker H, Beshansky J, Sheehan P, Massaro J, Griffith J, DAgostino R . Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA. 2012; 307(18):1925-33. PMC: 4167391. DOI: 10.1001/jama.2012.426. View

Ang D, Welsh P, Watt P, Nelson S, Struthers A, Sattar N . Serial changes in adiponectin and BNP in ACS patients: paradoxical associations with each other and with prognosis. Clin Sci (Lond). 2009; 117(1):41-8. DOI: 10.1042/CS20080506. View

10.

Aprahamian T, Sam F . Adiponectin in cardiovascular inflammation and obesity. Int J Inflam. 2011; 2011:376909. PMC: 3175407. DOI: 10.4061/2011/376909. View

11.

Shand B, Elder P, Scott R, Frampton C, Willis J . Biovariability of plasma adiponectin. Clin Chem Lab Med. 2006; 44(10):1264-8. DOI: 10.1515/CCLM.2006.227. View

12.

Zhang H, Cui J, Zhang C . Emerging role of adipokines as mediators in atherosclerosis. World J Cardiol. 2010; 2(11):370-6. PMC: 3006473. DOI: 10.4330/wjc.v2.i11.370. View

13.

Lawlor D, Davey Smith G, Ebrahim S, Thompson C, Sattar N . Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab. 2005; 90(10):5677-83. DOI: 10.1210/jc.2005-0825. View

14.

Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley R . Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001; 86(5):1930-5. DOI: 10.1210/jcem.86.5.7463. View

15.

Deng Y, Scherer P . Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci. 2011; 1212:E1-E19. PMC: 3075414. DOI: 10.1111/j.1749-6632.2010.05875.x. View

16.

Trifunovic D, Stankovic S, Marinkovic J, Beleslin B, Banovic M, Djukanovic N . Time-dependent changes of plasma adiponectin concentration in relation to coronary microcirculatory function in patients with acute myocardial infarction treated by primary percutaneous coronary intervention. J Cardiol. 2014; 65(3):208-15. DOI: 10.1016/j.jjcc.2014.05.011. View

17.

Phillips S, Kung J . Mechanisms of adiponectin regulation and use as a pharmacological target. Curr Opin Pharmacol. 2010; 10(6):676-83. DOI: 10.1016/j.coph.2010.08.002. View

18.

Sullivan A, Beshansky J, Ruthazer R, Murman D, Mader T, Selker H . Factors associated with longer time to treatment for patients with suspected acute coronary syndromes: a cohort study. Circ Cardiovasc Qual Outcomes. 2014; 7(1):86-94. PMC: 3985420. DOI: 10.1161/CIRCOUTCOMES.113.000396. View

19.

Pischon T, Hotamisligil G, Rimm E . Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem. 2003; 49(4):650-2. DOI: 10.1373/49.4.650. View

20.

Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y . Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999; 100(25):2473-6. DOI: 10.1161/01.cir.100.25.2473. View